Deferred Income Tax Expense (Benefit) of AbbVie Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
AbbVie Inc. annual and quarterly Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • AbbVie Inc. Deferred Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $28,000,000, a 93% increase year-over-year.
  • AbbVie Inc. annual Deferred Income Tax Expense (Benefit) for 2025 was $492,000,000, a 66% increase from 2024.
  • AbbVie Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $1,449,000,000, a 50% increase from 2023.
  • AbbVie Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $2,889,000,000, a 50% decline from 2022.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Change (%)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)

AbbVie Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $492,000,000 +$957,000,000 +66% 01 Jan 2025 31 Dec 2025 10-K 20 Feb 2026 2025 FY
2024 $1,449,000,000 +$1,440,000,000 +50% 01 Jan 2024 31 Dec 2024 10-K 20 Feb 2026 2025 FY
2023 $2,889,000,000 -$958,000,000 -50% 01 Jan 2023 31 Dec 2023 10-K 20 Feb 2026 2025 FY
2022 $1,931,000,000 -$1,033,000,000 -115% 01 Jan 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
2021 $898,000,000 +$1,427,000,000 +61% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $2,325,000,000 -$2,447,000,000 -2006% 01 Jan 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
2019 $122,000,000 +$1,639,000,000 01 Jan 2019 31 Dec 2019 10-K 18 Feb 2022 2021 FY
2018 $1,517,000,000 +$2,645,000,000 +64% 01 Jan 2018 31 Dec 2018 10-K 19 Feb 2021 2020 FY
2017 $4,162,000,000 -$3,366,000,000 -423% 01 Jan 2017 31 Dec 2017 10-K 21 Feb 2020 2019 FY
2016 $796,000,000 -$948,000,000 -624% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $152,000,000 +$532,000,000 01 Jan 2015 31 Dec 2015 10-K 16 Feb 2018 2017 FY
2014 $380,000,000 -$1,004,000,000 -161% 01 Jan 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
2013 $624,000,000 +$520,000,000 +500% 01 Jan 2013 31 Dec 2013 10-K 19 Feb 2016 2015 FY
2012 $104,000,000 +$436,000,000 01 Jan 2012 31 Dec 2012 10-K 20 Feb 2015 2014 FY
2011 $332,000,000 01 Jan 2011 31 Dec 2011 10-K 21 Feb 2014 2013 FY

AbbVie Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $28,000,000 +$361,000,000 +93% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q1 2024 $389,000,000 -$122,000,000 -46% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q1 2023 $267,000,000 -$73,000,000 -38% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q1 2022 $194,000,000 -$166,000,000 -593% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q1 2021 $28,000,000 +$153,000,000 +85% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $181,000,000 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.